

PRESS RELEASE

Date 24 May 2016
Contact Investor Relations: Julien Vignot, Head Investor Relations, Galenica Group
Media Relations: Christina Hertig, Head Corporate Communications, Galenica Group
Subject Vifor Pharma to license commercialisation rights to Pfizer's proposed biosimilar, Retacrit™, in the field of nephrology in the US

Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer's proposed epoetin alfa biosimilar, Retacrit™, in the US dialysis market

Vifor Pharma, a company of the Galenica group, has further expanded its Erythropoiesis Stimulating Agent (ESA) portfolio with the licensing of commercialisation rights in the US dialysis market to Pfizer's Retacrit™, a proposed biosimilar epoetin, in the field of nephrology.

Hospira, a Pfizer company, (NYSE: PFE) submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Retacrit™ in December 2014. Retacrit™ is under review for the treatment of anaemia associated with chronic kidney disease (CKD), renal failure as well as chemotherapy-induced anaemia. With access to Retacrit™, once approved, Vifor Pharma will be positioned to also offer a short-acting ESA to the US dialysis market.

For further information, please contact:

Media Relations:

Christina Hertig, Head Corporate Communications
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Investor Relations:

Julien Vignot, Head Investor Relations
Tel. +41 58 852 85 29
E-mail: investors@galenica.com

***Galenica** is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group's income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).*

For more information, please visit the company's website at www.galenica.com.

***Vifor Pharma**, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world.*

For more information, please visit the company's website at www.viforpharma.com.

Date 24 May 2015
Page 2/2
Subject Vifor Pharma to license commercialisation rights to Pfizer's proposed biosimilar, Retacrit™, in the US in the field of nephrology

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube, and like us on Facebook at Facebook.com/Pfizer.